2 years ago

ViaNautis Bio Raises $25 Million to Advance Nanomedicine Platform

  • ViaNautis Bio, a Cambridge, UK-based nanomedicine company, has secured $25 million in Series A funding

  • The round was led by 4BIO Capital, BGF, and UCB Ventures, with participation from the Cystic Fibrosis Foundation, Eli Lilly and Company, and existing investors

  • ViaNautis's polyNaut® platform, a versatile nano-engineered polymer technology, enables targeted intracellular delivery of a wide range of payloads, creating 'bionic nanoparticles.' The company intends to use the funding to accelerate product development, expand its team, and establish new laboratory facilities.

      • ProblemHealthcare

      "Delivering large molecules into cells for treatment is inefficient and often ineffective, particularly for genetic materials, limiting the potential of gene therapy for many diseases."

      Solution

      "ViaNautis' PolyNaut® platform is a nano-engineered polymer technology that can deliver a wide range of payloads, including large molecules and genetic materials, directly into the cell cytoplasm, enhancing therapeutic efficacy. This bionic nanoparticle approach overcomes limitations of current delivery methods, potentially revolutionizing treatments for various diseases."

      Covered on